AL amyloidosis of the mesentery is rare and it has been associated with an extremely poor prognosis. We herein report a case of AL amyloidosis with diffuse calcifications (>13 cm) throughout the mesentery. After treatment with daratumumab, bortezomib, and dexamethasone, the patient achieved a very good partial response (VGPR). However, even after continuing the treatment for over 14 months while maintaining VGPR and achieving a kidney organ response, diffuse calcifications remained throughout the mesentery. Although rare, AL amyloidosis should be considered in the differential diagnosis of mesenteric calcification.
Furukawa et al. (2026) studied this question.